Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

F7307

Sigma-Aldrich

Fotemustine

≥98% (HPLC)

Sinonimo/i:

(+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate, Muphoran, Mustophorane, P-[1-[[[(2-Chloroethyl)nitrosoamino]carbonyl]amino]ethyl]-phosphonic acid diethyl ester, S 10036

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C9H19ClN3O5P
Numero CAS:
92118-27-9
Peso molecolare:
315.69
Numero MDL:
MFCD00866278
Codice UNSPSC:
12352200
ID PubChem:
329799764
Per informazioni sul prodotto F7307, contatta il rappresentante o rivenditore Merck di zona. Contatta l'Assistenza Tecnica.

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

protect from light

Colore

light yellow

Solubilità

H2O: ≥1 mg/mL

Ideatore

Servier

Temperatura di conservazione

2-8°C

Stringa SMILE

CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O

InChI

1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
YAKWPXVTIGTRJH-UHFFFAOYSA-N

Azioni biochim/fisiol

Fotemustine is a third generation nitrosourea, chloroethylating agent used in the treatment of glioma and malignant melanoma.

Caratteristiche e vantaggi

This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard
GHS08

Avvertenze

Warning

Indicazioni di pericolo

H351

Consigli di prudenza

P281

Classi di pericolo

Carc. 2

Codice della classe di stoccaggio

13 - Non Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
082M4738V
010M4731

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Felice Vito Vitale et al.
Anticancer research, 31(12), 4553-4559 (2011-12-27)
Locoregional treatments represent a good option for patients suffering from hepatocellular carcinoma (HCC) not eligible for resection or transplantation. Locoregional approaches include a wide spectrum of therapeutic methods and hepatic intra-arterial drug infusion is also considered. Fotemustine is a chemotherapy
Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support.
Elsa Pennese et al.
Leukemia & lymphoma, 52(11), 2188-2189 (2011-07-02)
A Farolfi et al.
Journal of chemotherapy (Florence, Italy), 23(5), 300-305 (2011-10-19)
The liver is the primary site of metastases in most uveal melanoma patients. We retrospectively investigated intraarterial chemotherapy (IAC) as treatment for patients with hepatic melanoma metastases.Twenty-three patients (18 with uveal melanoma) received fotemustine (14 patients, 61.9%) or carboplatin (9
A Silvani et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 32 Suppl 2, S255-S257 (2011-10-12)
Fotemustine (FTMS) is a third-generation nitrosourea, in preclinical studies, FTMS compared favorably with carmustine (BCNU) and lomustine (CCNU) against several human tumor cell lines. In conventional schedule, FTMS is administered at a dose of 100 mg/sqm/week for three consecutive weeks
Mario Balducci et al.
Neuro-oncology, 14(1), 79-86 (2011-10-14)
We explored the feasibility of concurrent palliative chemotherapy and low-dose fractionated radiotherapy (LD-FRT) in glioblastoma multiforme (GBM). Patients with recurrent/progressive GBM at least 3 months after the end of primary radiotherapy received 0.3 Gy twice daily with cisplatin and fotemustine
Visualizza tutti i documenti correlati

Articoli

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.